Yun Zhong
Stock Analyst at Wedbush
(4.02)
# 990
Out of 5,182 analysts
52
Total ratings
58.7%
Success rate
10.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterates: Outperform | $273 | $245.38 | +11.26% | 5 | Apr 9, 2026 | |
| RZLT Rezolute | Upgrades: Outperform | $2 → $5 | $3.37 | +48.37% | 3 | Mar 25, 2026 | |
| IRD Opus Genetics | Maintains: Outperform | $8 → $10 | $5.54 | +80.51% | 2 | Mar 12, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $33 → $35 | $7.58 | +361.74% | 4 | Mar 6, 2026 | |
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $2.92 | +173.97% | 1 | Mar 5, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $21.42 | +58.73% | 13 | Jan 23, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $11.66 | +37.22% | 3 | Nov 6, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $105.47 | -18.46% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $17.89 | +0.61% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $6.25 | +540.00% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $6.44 | +334.78% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $4.23 | +89.13% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.51 | +77.38% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.86 | +729.02% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $3.65 | +667.12% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.46 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.46 | +10.65% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $18.04 | +154.99% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.34 | +2,867.36% | 1 | May 5, 2021 |
Ascendis Pharma
Apr 9, 2026
Reiterates: Outperform
Price Target: $273
Current: $245.38
Upside: +11.26%
Rezolute
Mar 25, 2026
Upgrades: Outperform
Price Target: $2 → $5
Current: $3.37
Upside: +48.37%
Opus Genetics
Mar 12, 2026
Maintains: Outperform
Price Target: $8 → $10
Current: $5.54
Upside: +80.51%
Wave Life Sciences
Mar 6, 2026
Maintains: Outperform
Price Target: $33 → $35
Current: $7.58
Upside: +361.74%
MannKind
Mar 5, 2026
Maintains: Outperform
Price Target: $10 → $8
Current: $2.92
Upside: +173.97%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $21.42
Upside: +58.73%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $11.66
Upside: +37.22%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $105.47
Upside: -18.46%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $17.89
Upside: +0.61%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $6.25
Upside: +540.00%
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $6.44
Upside: +334.78%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.23
Upside: +89.13%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.51
Upside: +77.38%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.86
Upside: +729.02%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $3.65
Upside: +667.12%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $6.46
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.46
Upside: +10.65%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $18.04
Upside: +154.99%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.34
Upside: +2,867.36%